Mediwound Ltd reports results for the quarter ended June 30 - Earnings Summary
Mediwound Ltd reports results for the quarter ended June 30 - Earnings Summary
Mediwound Ltd MDWD.OQ reported a quarterly adjusted loss of 57 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.23. The mean expectation of six analysts for the quarter was for a loss of 76 cents per share. Wall Street expected results to range from -91 cents to -68 cents per share.
Revenue fell 45.8% to $3.09 million from a year ago; analysts expected $2.59 million.
Mediwound Ltd's reported EPS for the quarter was a loss of 57 cents.
The company reported a quarterly loss of $7.39 million.
Mediwound Ltd shares had fallen by 5.4% this quarter and lost 24.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 7.8% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Mediwound Ltd is $31.00, about 55.1% above its last closing price of $13.91
This summary was machine generated from LSEG data August 13 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.76 | -0.57 | Beat |
Mar. 31 2026 | -0.65 | -0.23 | Beat |
Dec. 31 2025 | -0.63 | -0.56 | Beat |
Sep. 30 2025 | -0.81 | -0.24 | Beat |
Recent news on Mediwound
See all newsBrief: Mediwound Awarded Additional $3.3 Million From U.S. Department Of War To Advance Room-Temperature-Stable Formulation Of Nexobrid
Mediwound Ltd reports results for the quarter ended June 30 - Earnings Summary
Israel's MediWound beats Q2 revenue estimates, reaffirms 2026 guidance
Brief: MediWound Q2 EPS USD -0.57
Mediwound Ltd expected to post a loss of 76 cents a share - Earnings Preview